Funding allows Stem Cell to finish merger with South Korean firm

03/17/2009 | American City Business Journals

Stem Cell Therapy International said it has secured short-term funding to finalize its merger with HistoStem, a South Korean firm that manages a cord blood and stem cell bank, to create a firm called AmStem International. Under the merger, AmStem is expected to bring to the U.S. adult stem cells from Asia for use in clinical studies and treatments.

View Full Article in:

American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
In house Compliance Officer
Confidential
Pompano Beach, FL